Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (47) 47
cardiac & cardiovascular systems (37) 37
humans (36) 36
cardiovascular (33) 33
male (29) 29
female (28) 28
middle aged (26) 26
aged (21) 21
myocardial infarction (15) 15
peripheral vascular disease (15) 15
abridged index medicus (13) 13
risk factors (13) 13
medicine, general & internal (11) 11
stroke (11) 11
acute coronary syndromes (9) 9
angiography (9) 9
animals (9) 9
double-blind method (9) 9
hematology (9) 9
mortality (9) 9
follow-up studies (8) 8
prospective studies (8) 8
rats (8) 8
risk (8) 8
atrial fibrillation (7) 7
cells, cultured (7) 7
heart attacks (7) 7
ischemia (7) 7
management (7) 7
myocardial infarction - drug therapy (7) 7
patients (7) 7
acute coronary syndrome (6) 6
coronary artery disease (6) 6
myocardial-infarction (6) 6
outcomes (6) 6
treatment outcome (6) 6
cardiovascular diseases (5) 5
cardiovascular diseases - prevention & control (5) 5
care and treatment (5) 5
cerebral infarction (5) 5
drug therapy, combination (5) 5
heart (5) 5
heart attack (5) 5
heart failure (5) 5
nitric oxide synthase type ii (5) 5
prevention (5) 5
rats, sprague-dawley (5) 5
acute coronary syndrome - drug therapy (4) 4
adult (4) 4
analysis (4) 4
angina (4) 4
angina pectoris (4) 4
apoptosis - drug effects (4) 4
association (4) 4
cardiac myocytes (4) 4
cardiac patients (4) 4
cardiovascular disease (4) 4
cardiovascular diseases - mortality (4) 4
death (4) 4
diagnosis (4) 4
guidelines (4) 4
hemorrhage (4) 4
kaplan-meier estimate (4) 4
life sciences (4) 4
myocardium - metabolism (4) 4
nitric oxide (4) 4
obstetrics & gynecology (4) 4
percutaneous coronary intervention (4) 4
research (4) 4
sex factors (4) 4
therapy (4) 4
time factors (4) 4
aged, 80 and over (3) 3
atrial fibrillation - complications (3) 3
atrial fibrillation - drug therapy (3) 3
australia (3) 3
australia - epidemiology (3) 3
bleeding (3) 3
cells (3) 3
diabetes (3) 3
dose-response relationship, drug (3) 3
drug therapy (3) 3
electrocardiography (3) 3
electrocardiography, ambulatory (3) 3
health risk assessment (3) 3
heart - physiology (3) 3
heart diseases (3) 3
human health and pathology (3) 3
incidence (3) 3
myocardial infarction - physiopathology (3) 3
myocardial ischemia - diagnosis (3) 3
myocardial ischemia - epidemiology (3) 3
nitric oxide synthase - physiology (3) 3
oxidative stress (3) 3
patient outcomes (3) 3
pcsk9 (3) 3
predictive value of tests (3) 3
quality of life (3) 3
recurrence (3) 3
reduction (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
by Schwartz, Gregory G and Steg, P. Gabriel and Szarek, Michael and Bhatt, Deepak L and Bittner, Vera A and Diaz, Rafael and Edelberg, Jay M and Goodman, Shaun G and Hanotin, Corinne and Harrington, Robert A and Jukema, J. Wouter and Lecorps, Guillaume and Mahaffey, Kenneth W and Moryusef, Angèle and Pordy, Robert and Quintero, Kirby and Roe, Matthew T and Sasiela, William J and Tamby, Jean-François and Tricoci, Pierluigi and White, Harvey D and Zeiher, Andreas M and ODYSSEY OUTCOMES Comm Inv and ODYSSEY OUTCOMES Committees and Investigators
The New England Journal of Medicine, ISSN 0028-4793, 11/2018, Volume 379, Issue 22, pp. 2097 - 2107
Among patients who had had an acute coronary syndrome, the risk of death from coronary heart disease, nonfatal myocardial infarction, stroke, or unstable... 
MEDICINE, GENERAL & INTERNAL | MANAGEMENT | MYOCARDIAL-INFARCTION | TASK-FORCE | EFFICACY | SAFETY | LDL | REDUCING LIPIDS | PCSK9 | MONOCLONAL-ANTIBODY | ASSOCIATION | Double-Blind Method | Follow-Up Studies | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Male | Hypercholesterolemia - drug therapy | Anticholesteremic Agents - adverse effects | Acute Coronary Syndrome - blood | Acute Coronary Syndrome - drug therapy | Acute Coronary Syndrome - complications | Anticholesteremic Agents - therapeutic use | Proprotein Convertase 9 - antagonists & inhibitors | Cardiovascular Diseases - epidemiology | Adult | Cholesterol, LDL - blood | Female | Hypercholesterolemia - complications | Aged | Acute coronary syndrome | Diagnosis | Myocardial infarction | Fees & charges | Lipoproteins (low density) | Heart attacks | Lipids | Cardiovascular disease | Angina | Apolipoprotein B | Ischemia | Heart diseases | Drug dosages | Statins | Cerebral infarction | Stroke | Subtilisin | Apolipoproteins | Angina pectoris | Patients | Low density lipoprotein | Coronary artery disease | Cholesterol | Kexin | Monoclonal antibodies | Full text | Acute coronary syndromes | Cardiovascular diseases | Health risk assessment | Pharmaceuticals | Index Medicus | Abridged Index Medicus | Life Sciences | Human health and pathology | Cardiology and cardiovascular system
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction
by Bonaca, Marc P and Bhatt, Deepak L and Cohen, Marc and Steg, Philippe Gabriel and Storey, Robert F and Jensen, Eva C and Magnani, Giulia and Bansilal, Sameer and Fish, M. Polly and Im, Kyungah and Bengtsson, Olof and Ophuis, Ton Oude and Budaj, Andrzej and Theroux, Pierre and Ruda, Mikhail and Hamm, Christian and Goto, Shinya and Spinar, Jindrich and Nicolau, José Carlos and Kiss, Robert G and Murphy, Sabina A and Wiviott, Stephen D and Held, Peter and Braunwald, Eugene and Sabatine, Marc S and PEGASUS-TIMI 54 Steering Comm and PEGASUS-TIMI 54 Steering Committee and Investigators
The New England Journal of Medicine, ISSN 0028-4793, 05/2015, Volume 372, Issue 19, pp. 1791 - 1800
Patients with myocardial infarction 1 to 3 years previously were assigned to ticagrelor, 90 or 60 mg twice daily, or to placebo, in addition to low-dose... 
MEDICINE, GENERAL & INTERNAL | HEART-DISEASE | CLOPIDOGREL | MANAGEMENT | ESC GUIDELINES | AMERICAN-COLLEGE | PREVENTION | ASSOCIATION TASK-FORCE | ACUTE CORONARY SYNDROMES | PRASUGREL | ASPIRIN | Purinergic P2Y Receptor Antagonists - administration & dosage | Double-Blind Method | Drug Administration Schedule | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Kaplan-Meier Estimate | Male | Risk | Secondary Prevention | Adenosine - administration & dosage | Aspirin - administration & dosage | Purinergic P2Y Receptor Antagonists - adverse effects | Myocardial Infarction - drug therapy | Adenosine - adverse effects | Adenosine - analogs & derivatives | Intracranial Hemorrhages - chemically induced | Platelet Aggregation Inhibitors - administration & dosage | Cardiovascular Diseases - mortality | Female | Aged | Hemorrhage - chemically induced | Drug Therapy, Combination | Platelet Aggregation Inhibitors - adverse effects | Dose-response relationship (Biochemistry) | Treatment outcome | Care and treatment | Safety and security measures | Analysis | Dosage and administration | Ticagrelor | Heart attack | Risk factors | Myocardial infarction | Cerebral infarction | Aspirin | Stroke | Heart attacks | Hemorrhage | Long term | Patients | Thrombolysis | Bleeding | Blood platelets | Antagonist drugs | Cardiovascular diseases | Drug therapy | Index Medicus | Abridged Index Medicus | Life Sciences | Human health and pathology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Edoxaban versus Warfarin in Patients with Atrial Fibrillation
by Giugliano, Robert P and Ruff, Christian T and Braunwald, Eugene and Murphy, Sabina A and Wiviott, Stephen D and Halperin, Jonathan L and Waldo, Albert L and Ezekowitz, Michael D and Weitz, Jeffrey I and Špinar, Jindřich and Ruzyllo, Witold and Ruda, Mikhail and Koretsune, Yukihiro and Betcher, Joshua and Shi, Minggao and Grip, Laura T and Patel, Indravadan and Patel, Shirali P and Hanyok, James J and Mercuri, Michele and Antman, Elliott M and ENGAGE AF-TIMI 48 Investigators
The New England Journal of Medicine, ISSN 0028-4793, 11/2013, Volume 369, Issue 22, pp. 2093 - 2104
Edoxaban, an oral factor Xa inhibitor, was noninferior to warfarin in the prevention of stroke or systemic embolism in patients with atrial fibrillation. There... 
STROKE | MEDICINE, GENERAL & INTERNAL | METAANALYSIS | PHARMACOKINETICS | SAFETY | ORAL ANTICOAGULANTS | PREVENTION | GENERATION | FACTOR XA INHIBITOR | Stroke - prevention & control | Embolism - prevention & control | Double-Blind Method | Follow-Up Studies | Atrial Fibrillation - drug therapy | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Atrial Fibrillation - complications | Kaplan-Meier Estimate | Warfarin - adverse effects | Anticoagulants - therapeutic use | Male | Thiazoles - therapeutic use | Anticoagulants - adverse effects | Thiazoles - adverse effects | Warfarin - therapeutic use | Pyridines - adverse effects | Cardiovascular Diseases - mortality | Adult | Female | Aged | Hemorrhage - chemically induced | Pyridines - therapeutic use | Warfarin | Anticoagulants (Medicine) | Research | Comparative analysis | Drug therapy | Atrial fibrillation | Fees & charges | Cardiac arrhythmia | Stroke | Heart attacks | Risk groups | Glycoproteins | Patients | Bleeding | Embolism | Manuscripts | Fibrillation | Motivation | Death | Thromboembolism | Drug dosages | Pharmaceuticals | Index Medicus | Abridged Index Medicus | Anticoagulants | Cardiovascular Diseases | Enoxaparin | Hemorrhage | Life Sciences | Atrial Fibrillation
Journal Article
Details down arrow
Digital rights down arrow